These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
232 related articles for article (PubMed ID: 30404037)
1. Obliterative Portal Venopathy Without Cirrhosis Is Prevalent in Pediatric Cystic Fibrosis Liver Disease With Portal Hypertension. Wu H; Vu M; Dhingra S; Ackah R; Goss JA; Rana A; Quintanilla N; Patel K; Leung DH Clin Gastroenterol Hepatol; 2019 Sep; 17(10):2134-2136. PubMed ID: 30404037 [TBL] [Abstract][Full Text] [Related]
2. Liver transplantation in precirrhotic biliary tract disease: Portal hypertension is frequently associated with nodular regenerative hyperplasia and obliterative portal venopathy. Abraham SC; Kamath PS; Eghtesad B; Demetris AJ; Krasinskas AM Am J Surg Pathol; 2006 Nov; 30(11):1454-61. PubMed ID: 17063088 [TBL] [Abstract][Full Text] [Related]
3. Non-cirrhotic portal hypertension (obliterative portal venopathy) is the predominant form of chronic liver disease in cystic fibrosis. ONeill JP; Clifford CS; Nolan NP; McCormick PA Ir J Med Sci; 2023 Aug; 192(4):1657-1660. PubMed ID: 36114932 [TBL] [Abstract][Full Text] [Related]
4. Liver transplantation in adult cystic fibrosis: Clinical, imaging, and pathological evidence of obliterative portal venopathy. Hillaire S; Cazals-Hatem D; Bruno O; de Miranda S; Grenet D; Poté N; Soubrane O; Erlinger S; Lacaille F; Mellot F; Vilgrain V; Paradis V Liver Transpl; 2017 Oct; 23(10):1342-1347. PubMed ID: 28816015 [No Abstract] [Full Text] [Related]
5. Features of Severe Liver Disease With Portal Hypertension in Patients With Cystic Fibrosis. Stonebraker JR; Ooi CY; Pace RG; Corvol H; Knowles MR; Durie PR; Ling SC Clin Gastroenterol Hepatol; 2016 Aug; 14(8):1207-1215.e3. PubMed ID: 27062904 [TBL] [Abstract][Full Text] [Related]
16. Genetic modifiers of liver disease in cystic fibrosis. Bartlett JR; Friedman KJ; Ling SC; Pace RG; Bell SC; Bourke B; Castaldo G; Castellani C; Cipolli M; Colombo C; Colombo JL; Debray D; Fernandez A; Lacaille F; Macek M; Rowland M; Salvatore F; Taylor CJ; Wainwright C; Wilschanski M; Zemková D; Hannah WB; Phillips MJ; Corey M; Zielenski J; Dorfman R; Wang Y; Zou F; Silverman LM; Drumm ML; Wright FA; Lange EM; Durie PR; Knowles MR; JAMA; 2009 Sep; 302(10):1076-83. PubMed ID: 19738092 [TBL] [Abstract][Full Text] [Related]
17. A Multidisciplinary Approach to Pretransplant and Posttransplant Management of Cystic Fibrosis-Associated Liver Disease. Freeman AJ; Sellers ZM; Mazariegos G; Kelly A; Saiman L; Mallory G; Ling SC; Narkewicz MR; Leung DH Liver Transpl; 2019 Apr; 25(4):640-657. PubMed ID: 30697907 [TBL] [Abstract][Full Text] [Related]
18. Analysis of a large cohort of cystic fibrosis patients with severe liver disease indicates lung function decline does not significantly differ from that of the general cystic fibrosis population. Polineni D; Piccorelli AV; Hannah WB; Dalrymple SN; Pace RG; Durie PR; Ling SC; Knowles MR; Stonebraker JR PLoS One; 2018; 13(10):e0205257. PubMed ID: 30307979 [TBL] [Abstract][Full Text] [Related]